SOFAR has been 100% owned by FINE FOODS & PHARMACEUTICALS since April 2026.

At what enterprise value was SOFAR acquired in 2026?

During the acquisition of SOFAR by FINE FOODS & PHARMACEUTICALS in 2026, the transaction's Enterprise Value is estimated to be in the range of €10–30M.

What was the EV/EBITDA of SOFAR when it was acquired by FINE FOODS & PHARMACEUTICALS?

The estimated EV/EBITDA multiple for SOFAR is in the range of below 5x.

What was the EV/Revenue multiple of SOFAR when it was acquired by FINE FOODS & PHARMACEUTICALS?

The estimated EV/Revenue multiple for SOFAR is in the range of below 1.5x.

When was SOFAR acquired by FINE FOODS & PHARMACEUTICALS?

SOFAR was acquired by FINE FOODS & PHARMACEUTICALS in 2026.

What was the revenue of SOFAR at the time of the deal?

The revenue of SOFAR at the time of the deal is estimated to be in the range of €25–50M.

What was the EBITDA of SOFAR during the acquisition?

SOFAR's EBITDA is estimated to be in the range of €5–25M.

How is the data for the SOFAR acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SOFAR deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.finefoods.it/wp-content/uploads/2026/04/FF_Press-Release-17-april-2026.pdf

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaSOFAR

04/2026

SOFAR acquired by FINE FOODS & PHARMACEUTICALS

ITALY Life Sciences / Pharma & Biotech / CDMO EV €10–30M

Context

The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities. The strategic rationale for this transaction centers on a "technology-integration" play, merging the target's industry-leading expertise in liquid and semi-solid pharmaceuticals with the group’s established global leadership in the CSDMO sector. This fusion effectively creates a specialized powerhouse in the contract manufacturing arena, providing the organization with the technical operational depth required to address the increasing demand for diverse dosage forms. This operation allows the group to execute a definitive structural expansion of its service portfolio, specifically targeting the pharmaceutical and nutraceutical end-markets. By incorporating the target's innovative production facility, the organization can now provide a more robust and integrated solution set for strategic partners looking for comprehensive development support.

SOFAR, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of below 5x, a level significantly lower than the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

SOFAR S.p.A. operates as a premier technology organization dedicated to the engineering and distribution of specialized pharmaceutical and nutraceutical solutions. The entity’s business model is centered on a proprietary framework of manufacturing capabilities for liquid and semi-solid dosage forms, providing critical production infrastructure for the microelectronic-precision pharmaceutical industry. Its value proposition is anchored in technical operational depth, offering specialized services for the development of high-quality formulations across diverse therapeutic areas. Strategically, the firm focuses on maintaining industrialized quality standards and operational excellence within its specialized production facilities. By maintaining a specialized focus on technical reliability and complex manufacturing processes, the organization ensures a vital role in the structural advancement of the healthcare supply chain. The entity prioritizes industrialized efficiency and standardized production protocols to facilitate the structural advancement of therapeutic delivery systems.

Ent. Value

€10–30M

Equity Value

[members only]

Multiples

EV / Revenue

below 1.5x

EV / EBITDA

below 5x

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2026	3I	LABORATOIRE NUTERGIA	FRANCE	Nutrition & Dietary Supplements
05/2026	STRYKER	AMPLITUDE VASCULAR SYSTEMS	UNITED STATES	Medical Devices
04/2026	HALMA	SURGISTAR	UNITED STATES	Medical Devices
04/2026	UCB	NEURONA THERAPEUTICS	UNITED STATES	R&D Biotech
04/2026	REVENIO GROUP CORPORATION	VISIONIX INTERNATIONAL	FRANCE	Diagnostic Equipment
04/2026	VITREX MEDICAL GROUP	HERNIAMESH	ITALY	Implants & Prosthetics
04/2026	DEVYSER DIAGNOSTICS	CYBERGENE	SWEDEN	Diagnostic Equipment
04/2026	AMERICAN INDUSTRIAL PARTNERS AIP	AVANOS MEDICAL	UNITED STATES	Medical Consumables
04/2026	OURY MEDICAL	CÉFIMÉCA	FRANCE	Implants & Prosthetics
04/2026	FOR TALENTS / UI INVESTISSEMENT / GENEO	NEFTYS PHARMA	FRANCE	Animal Health

REFERENCES

Valuation range: EV €10–30M

Revenue range: €25–50M

EBITDA range: €5–25M

EV/Revenue range: below 1.5x

EV/EBITDA range: below 5x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SOFAR by FINE FOODS & PHARMACEUTICALS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.